

March 31, 2025

Perseus Proteomics Inc.

Securities Code: 4882 Growth TSE

email: [ir@ppmx.com](mailto:ir@ppmx.com)

### **Notice on Full-Year Business Results Forecasts**

Perseus Proteomics Inc. (the “Company”) has calculated the business forecasts for the fiscal year ending March 31, 2025, which were previously undetermined, as below.

#### 1. Non-consolidated financial results forecasts for the FY2025/3

	Net sales	Operating income	Ordinary income	Profit	Earnings per share
Previously announced forecasts (A)	-	-	-	-	-
Revised forecasts (B)	120	(843)	(846)	(920)	(64.49)
Change (B-A)	-	-	-	-	-
Change (%)	-	-	-	-	-
(Reference) Actual Non-consolidated results for FY2024/3	100	(894)	(879)	(1,104)	(93.69)

#### 2. Reasons for disclosure

Due to the difficulty in rationally forecasting the impact of the licensing agreements for PPMX-T002 and PPMX-T003 on sales and others in the fiscal year ending March 31, 2025, the Company has decided not to provide the business results forecasts. The Company has been actively pursuing licensing activities of the pipeline projects, however, they have not yet been completed at this time. Therefore, the Company is now disclosing the business results forecasts calculated based on the information and projections currently available.

With regards to costs, the Company expects R&D expenses of 611 million yen and other administration expenses of 336 million yen, resulting in SG & A expenses of 947 million yen.

#### 3. Future activities

The Company will continue licensing activities of both pipeline projects aiming at maximization of their value.

Actual results may differ from the forecasts due to various factors.

END